|
1
|
Islam S, Kitagawa T, Baron B, Abiko Y,
Chiba I and Kuramitsu Y: ITGA2, LAMB3, and LAMC2 may be the
potential therapeutic targets in pancreatic ductal adenocarcinoma:
An integrated bioinformatics analysis. Sci Rep. 11:105632021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amrutkar M and Gladhaug IP: Pancreatic
cancer chemoresistance to gemcitabine. Cancers (Basel). 9:1572017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamaguchi H and Condeelis J: Regulation of
the cytoskeleton in cancer cell migration and invation. Biochim
Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yin M, Ma W and An L: Cortactin in cancer
cell migration and invasion. Oncotarget. 8:88232–88243. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kamiyama Y, Matsui Y, Kawaguchi Y, Kosuna
K and Wakame K: Active hexose correlated compound (AHCC).
Biotherapy. 14:959–964. 2000.
|
|
6
|
Kidd P: The use of mushroom glucans and
proteoglycans in cancer treatment. Altern Med Rev. 5:4–27.
2000.PubMed/NCBI
|
|
7
|
Ye SF, Ichimura K, Wakame K and Ohe M:
Suppressive effects of active hexose correlated compound on the
increased activity of hepatic and renal ornithine decarboxylase
induced by oxidative stress. Life Sci. 74:593–602. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuhara K, Tokuda K, Kitagawa T, Baron B,
Tokunaga M, Harada K, Terasaki M, Uehara O, Ohta T, Takai R, et al:
CUB domain-containing protein 1 (CDCP1) is down-regulated by active
hexose-correlated compound in human pancreatic cancer cells.
Anticancer Res. 38:6107–6111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suenaga S, Kuramitsu Y, Kaino S, Maehara
S-I, Maehara Y, Sakaida I and Nakamura K: Active hexose-correlated
compound down-regulates HSP27 of pancreatic cancer cells, and helps
the cytotoxic effect of gemcitabine. Anticancer Res. 34:141–146.
2014.PubMed/NCBI
|
|
10
|
Tokunaga M, Baron B, Kitagawa T, Tokuda K
and Kuramitsu Y: Active hexose-correlated compound down-regulates
heat shock factor 1, a transcription factor for HSP27, in
gemcitabine-resistant human pancreatic cancer cells. Anticancer
Res. 35:6063–6067. 2015.PubMed/NCBI
|
|
11
|
Nawata J, Kuramitsu Y, Wang Y, Kitagawa T,
Tokuda K, Baron B, Akada J, Suenaga S, Kaino S, Maehara S, et al:
Active hexose-correlated compound down-regulates sex-determining
region Y-box 2 of pancreatic cancer cells. Anticancer Res.
34:4807–4811. 2014.PubMed/NCBI
|
|
12
|
Mori-Iwamoto S, Kuramitsu Y, Ryozawa S,
Mikuria K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K
and Sakaida I: Proteomics finding heat shock protein 27 as a
biomarker for resistance of pancreatic cancer cells to gemcitabine.
Int J Oncol. 31:1345–1350. 2007.PubMed/NCBI
|
|
13
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maehara S, Tanaka S, Shimada M, Shirabe K,
Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor
for evaluating gemcitabine resistance in human pancreatic cancer
cells. Int J Cancer. 112:184–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Belkourchia F and Desrosiers R: The enzyme
L-isoaspartyl (D-aspartyl) methyltransferase promotes migration and
invasion in human U-87 MG and U-251 MG glioblastoma cell lines.
Biomed Pharmacother. 140:1117662021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Islam S, Uehara O, Matsuoka H, Kuramitsu
Y, Adhikari BR, Hiraki D, Toraya S, Jayawardena A, Saito I,
Muthumala M, et al: DNA hypermethylation of sirtuin 1 (SIRT1)
caused by betel quid chewing-a possible predictive biomarker for
malignant transformation. Clin Epigenetics. 12:122020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsushita K, Kuramitsu Y, Ohiro Y, Obara
M, Kobayashi M, Li YQ and Hosokawa M: Combination therapy of active
hexose correlated compound plus UFT significantly reduces the
metastasis of rat mammary adenocarcinoma. Anticancer Drugs.
9:343–350. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cowawintaweewat S, Manoromana S, Sriplung
H, Khuhaprema T, Tongtawe P, Tapchaisri P and Chaicumpa W:
Prognostic improvement of patients with advanced liver cancer after
active hexose correlated compound (AHCC) treatment. Asian Pac J
Allergy Immunol. 24:33–45. 2006.PubMed/NCBI
|
|
20
|
Hunter RJ, Fujii H, Wakame K, Gaikwad A,
Wolf JK and Smith JA: Evaluation of active hexose correlated
compound (AHCC) in combination with pegylated liposomal doxorubicin
for treatment of ovarian cancer. Int J Appl Res Nat Prod. 4:6–11.
2011.
|
|
21
|
Hangai S, Iwase S, Kawaguchi T, Kogure Y,
Miyaji T, Matsunaga T, Nagumo Y and Yamaguchi T: Effect of active
hexose-correlated compound in women receiving adjuvant chemotherapy
for breast cancer: A retrospective study. J Altern Complement Med.
19:905–910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haidari M, Zhang W and Wakame K:
Disruption of endothelial adherens junction by invasive breast
cancer cells is mediated by reactive oxygen species and is
attenuated by AHCC. Life Sci. 93:994–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito T, Urushima H, Sakaue M, Yukawa S,
Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T and Kondo
K: Reduction of adverse effects by a mushroom product, active
hexose correlated compound (AHCC) in patients with advanced cancer
during chemotherapy-the significance of the levels of HHV-6 DNA in
saliva as a surrogate biomarker during chemotherapy. Nutr Cancer.
66:377–382. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF
and Kim SK: Therapeutic effect of active hexose-correlated compound
(AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma
murine model. Cytokine. 76:131–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao Z, Chen X, Lan L, Zhang Z, Du J and
Liao L: Active hexose correlated compound potentiates the antitumor
effects of low-dose 5-fluorouracil through modulation of immune
function in hepatoma 22 tumor-bearing mice. Nutr Res Pract.
9:129–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yanagimoto H, Satoi S, Yamamoto T, Hirooka
S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, et
al: Alleviating effect of active hexose correlated compound (AHCC)
on chemotherapy-related adverse events in patients with
unresectable pancreatic ductal adenocarcinoma. Nutr Cancer.
68:234–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Graham ÉA, Mallet JF, Jambi M, Nishioka H,
Homma K and Matar C: MicroRNA signature in the chemoprevention of
functionally-enriched stem and progenitor pools (FESPP) by active
hexose correlated compound (AHCC). Cancer Biol Ther. 18:765–774.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fatehchand K, Santhanam R, Shen B,
Erickson EL, Gautam S, Elavazhagan S, Mo X, Belay T, Tridandapani S
and Butchar JP: Active hexose-correlated compound enhances
extrinsic-pathway-mediated apoptosis of acute myeloid leukemic
cells. PLoS One. 12:e01817292017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi JY, Lee S, Yun SM, Suh DH, Kim K, No
JH, Jeong EH and Kim YB: Active hexose correlated compound (AHCC)
inhibits the proliferation of ovarian cancer cells by suppressing
signal transducer and activator of transcription 3 (STAT3)
activation. Nutr Cancer. 70:109–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suknikhom W, Lertkhachonsuk R and Manchana
T: The effects of active hexose correlated compound (AHCC) on
levels of CD4+ and CD8+ in patients with epithelial ovarian cancer
or peritoneal cancer receiving platinum based chemotherapy. Asian
Pac J Cancer Prev. 18:633–638. 2017.PubMed/NCBI
|
|
31
|
Buday L and Downward J: Roles of cortactin
in tumor pathogenesis. Biochim Biophys Acta. 1775:263–273.
2007.PubMed/NCBI
|
|
32
|
Ammer AG and Weed S: Cortactin branches
out: Roles in regulating protrusive actin dynamics. Cell Motil
Cytoskeleton. 65:687–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He J, Xia TS and Wang S: Cortactin and
tumor invasiveness. Chin J Cancer Prev Treat. 22:72–75, 80.
2015.
|
|
34
|
Stock K, Borrink R, Mikesch JH, Hansmeier
A, Rehkämper J, Trautmann M, Wardelmann E, Hartmann W, Sperveslage
J and Steinestel K: Overexpression and Tyr421-phosphorylation of
cortactin is induced by three-dimensional spheroid culturing and
contributes to migration and invasion of pancreatic ductal
adenocarcinoma (PDAC) cells. Cancer Cell Int. 19:772019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Patel AS, Schlechter GL, Wasilenko WJ and
Somers KD: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts
causes increased cell motility and invasion in vitro. Oncogene.
16:3227–3232. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang C, Liu J, Haudenschild CC and Zhan
X: The role of tyrosine phosphorylation of cortactin in the
locomotion of endothelial cells. J Biol Chem. 273:25770–25776.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tehrani S, Tomasevic N, Weed S, Sakowicz R
and Cooper J: Src phosphorylation of cortactin enhances actin
assembly. Proc Natl Acad Sci USA. 104:11933–11938. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Head JA, Jiang D, Li M, Zorn LJ, Schaefer
EM, Parsons JT and Weed SA: Cortactin tyrosine phosphorylation
requires Rac1 activity and association with the cortical actin
cytoskeleton. Mol Biol Cell. 14:3216–3229. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bowden ET, Onikoyi E, Tidwell R, Myoui A,
Yoneda T, Yamada KM and Mueller SC: Co-localization of cortactin
and phosphotyrosine identifies active invadopodia in human breast
cancer cells. Exp Cell Res. 312:1240–1253. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu C, Sun M, Liu L and Zhou W: The
function of the protein tyrosine phosphatase SHP-1 in cancer. Gene.
306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Frank C, Burkhardt C, Imhof D, Ringel J,
Zschörnig O, Wieligmann K, Zacharias M and Böhmer FD: Effective
dephosphorylation of Src substrates by SHP-1. J Biol Chem.
279:11375–11383. 2004. View Article : Google Scholar : PubMed/NCBI
|
